Globally and Locally Reduced MRI Gray Matter Volumes in Neuroleptic-Naive Men With Schizotypal Personality Disorder

Takeshi Asami, MD, PhD; Thomas J. Whitford, PhD; Sylvain Bouix, PhD; Chandlee C. Dickey, MD; Margaret Niznikiewicz, PhD; Martha E. Shenton, PhD; Martina M. Voglmaier, PhD; Robert W. McCarley, MD

Importance: Some, but not all, previous magnetic resonance imaging studies have indicated smaller cortical and local gray matter volumes (GMVs) in men with schizotypal personality disorder (SPD) compared with healthy control (HC) subjects. Thus, there is need for a whole-brain comparison to resolve inconsistencies and provide hitherto generally absent data on the association between GMV and symptoms.

Objective: To use voxel-based morphometry to evaluate a large sample of neuroleptic-naive men with SPD compared with group-matched HC subjects on local and global GMV and to identify associations with symptoms, especially negative symptoms. Also, to determine whether age-related GMV reductions are greater in men with SPD than HC subjects, providing presumptive evidence on possible progression.

Design, Setting, and Participants: This naturalistic study involved 54 neuroleptic-naive men with SPD and 54 male HC subjects aged 18 to 55 years recruited from the community and scanned on the same 1.5-T GE magnetic resonance imaging scanner. Participants were group matched on age, socioeconomic status, handedness, and IQ.

Main Outcome Measures: Cross-sectional voxel-based morphometry, GMV in subjects with SPD and HC participants, and the relationship to clinical symptoms.

Results: A voxelwise analysis showed participants with SPD had significantly smaller GMV in the left superior temporal gyrus and widespread frontal, frontolimbic, and parietal regions compared with HC subjects. Most of these regional volumes were strikingly and significantly correlated with negative symptoms: the more the volume reduction, the more negative symptoms. Global cortical GMV and most regional GMV showed significant negative relationships with age in both those with SPD and HC subjects, without any group by age interactions.

Conclusions and Relevance: Men with SPD showed global and widespread smaller regional GMV. The regional structural abnormalities were correlated with the severity of a participant’s negative symptoms. While the pattern of GMV loss is similar to that in schizophrenia, the similar patterns of HC-SPD age-related GMV reduction suggest that SPD showed no progressive GMV loss, pointing to an important difference in the biological mechanisms of SPD and schizophrenia.
Table 1. Previous Structural Imaging Studies of SPD

<table>
<thead>
<tr>
<th>Source</th>
<th>No. of Subjects (Male/Female)</th>
<th>Clinical or Community Based</th>
<th>Medication</th>
<th>Method</th>
<th>Differences in Gray Matter Volumes in Subjects With SPD vs HC Subjects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dickey et al., 1999</td>
<td>SPD: 15/0 HC: 14/0</td>
<td>Community</td>
<td>NN</td>
<td>ROI</td>
<td>Left STG(↓), amyg, hipp, parahipp →</td>
</tr>
<tr>
<td>Dickey et al., 2000</td>
<td>SPD: 16/0 HC: 14/0</td>
<td>Community</td>
<td>NN</td>
<td>ROI</td>
<td>Cortex(↓) in trend</td>
</tr>
<tr>
<td>Dickey et al., 2002</td>
<td>SPD: 21/0 HC: 22/0</td>
<td>Community</td>
<td>NN</td>
<td>ROI</td>
<td>Left Heschl gyrus(↓)</td>
</tr>
<tr>
<td>Levitt et al., 2002</td>
<td>SPD: 15/0 HC: 14/0</td>
<td>Community</td>
<td>NN</td>
<td>ROI</td>
<td>Bilateral caudate nucleus(↓)</td>
</tr>
<tr>
<td>Dickey et al., 2003</td>
<td>SPD: 21/0 HC: 19/0</td>
<td>Community</td>
<td>NN</td>
<td>ROI</td>
<td>Fusiform gyrus →</td>
</tr>
<tr>
<td>Dickey et al., 2008</td>
<td>SPD: 13/0 HC: 13/0</td>
<td>Community</td>
<td>NN</td>
<td>ROI</td>
<td>Heschl gyrus →</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Male SPD Study</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Koo et al., 2006</td>
<td>SPD: 0/32 HC: 0/29</td>
<td>Community</td>
<td>NN</td>
<td>ROI</td>
<td>STG (→) left STG (↓) in SPD with family history of major mental illness ((n = 9))</td>
</tr>
<tr>
<td>Koo et al., 2006</td>
<td>SPD: 0/31 HC: 0/29</td>
<td>Community</td>
<td>NN</td>
<td>ROI</td>
<td>Bilateral caudate nucleus(↓)</td>
</tr>
<tr>
<td>Koo et al., 2006</td>
<td>SPD: 0/32 HC: 0/29</td>
<td>Community</td>
<td>NN</td>
<td>ROI</td>
<td>Bilateral neocortex(↓)</td>
</tr>
<tr>
<td>Dickey et al., 2007</td>
<td>SPD: 0/20 HC: 0/29</td>
<td>Community</td>
<td>NN</td>
<td>ROI</td>
<td>Bilateral hipp(↓)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Female SPD Study</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Downhill Jr et al., 2001</td>
<td>SPD: 12/1 HC: 23/8</td>
<td>Clinical ((n = 11))</td>
<td>UM or NN</td>
<td>ROI</td>
<td>STG (↓), temporal structures without STG (↓)</td>
</tr>
<tr>
<td>Shihabuddin et al., 2001</td>
<td>SPD: 15/1 HC: 35/12</td>
<td>Both</td>
<td>NN ((n = 10)) UM at least 2 w ((n = 6))</td>
<td>ROI</td>
<td>Putamen(↓), caudate nucleus (→)</td>
</tr>
<tr>
<td>Takahashi et al., 2002</td>
<td>SPD: 12/12 HC: 24/24</td>
<td>Clinical</td>
<td>NN ((n = 2)) NL ((n = 22))</td>
<td>ROI</td>
<td>Anterior cingulate gyrus (→)</td>
</tr>
<tr>
<td>Yoneyama et al., 2003</td>
<td>SPD: 15/1 HC: 35/12</td>
<td>Clinical</td>
<td>UM at scan ((n = 3)) NL ((n = 11))</td>
<td>VBM</td>
<td>Bilateral insula(↓), left entorhinal region(↓)</td>
</tr>
<tr>
<td>Kawasaki et al., 2004</td>
<td>SPD: 14/11 HC: 28/22</td>
<td>Clinical</td>
<td>NN ((n = 2)) Med ((n = 23))</td>
<td>VBM</td>
<td>Left IFG, insula, STG, medial temporal region(↓)</td>
</tr>
<tr>
<td>Takahashi et al., 2004</td>
<td>SPD: 14/12 HC: 30/31</td>
<td>Clinical</td>
<td>NN ((n = 2)) NL ((n = 24))</td>
<td>ROI</td>
<td>Perigenual cingulate gyrus (→)</td>
</tr>
<tr>
<td>Haznedar et al., 2004</td>
<td>SPD: 12/1 HC: 25/7</td>
<td>NA</td>
<td>NA</td>
<td>ROI</td>
<td>Cingulate gyrus (→)</td>
</tr>
<tr>
<td>Suzuki et al., 2005</td>
<td>SPD: 15/10 HC: 35/24</td>
<td>Clinical</td>
<td>NN ((n = 6)) NL ((n = 19))</td>
<td>ROI</td>
<td>Bilateral amyg, hipp(↓), MFG(↑), right straight gyrus(↓)</td>
</tr>
<tr>
<td>Takahashi et al., 2005</td>
<td>SPD: 24/13 HC: 35/34</td>
<td>Clinical</td>
<td>NN ((n = 5)) NL ((n = 32))</td>
<td>ROI</td>
<td>Insula (→)</td>
</tr>
<tr>
<td>Takahashi et al., 2006</td>
<td>SPD: 24/15 HC: 38/34</td>
<td>Clinical</td>
<td>NN ((n = 5)) NL ((n = 34))</td>
<td>ROI</td>
<td>Bilateral caudal STG(↓), left PT(↓)</td>
</tr>
<tr>
<td>Takahashi et al., 2006</td>
<td>SPD: 24/15 HC: 38/34</td>
<td>Clinical</td>
<td>NN ((n = 5)) NL ((n = 34))</td>
<td>ROI</td>
<td>Posterior fusiform gyrus(↓)</td>
</tr>
<tr>
<td>Zhou et al., 2007</td>
<td>SPD: 15/10 HC: 35/24</td>
<td>Clinical</td>
<td>NN ((n = 6)) NL ((n = 29))</td>
<td>ROI</td>
<td>Left postcentral gyrus(↓), bilateral SPG(↓) in trend</td>
</tr>
<tr>
<td>Hazlett et al., 2008</td>
<td>SPD: 62/17 HC: 42/15</td>
<td>Clinical ((10%)), Community ((90%))</td>
<td>NvM ((n = 61))</td>
<td>Atlas</td>
<td>Cingulate gyrus(↓), left MTG(↓)</td>
</tr>
<tr>
<td>Goldstein et al., 2009</td>
<td>SPD: 16/11 HC: 19/26</td>
<td>NA</td>
<td>UM at scan</td>
<td>Atlas</td>
<td>STG ((BA22)) (↓), cingulate gyrus(↓) in trend</td>
</tr>
</tbody>
</table>

| Longitudinal ROI Study       |                               |                           |            | ROI    |                                                                   |
|------------------------------|-------------------------------|----------------------------|------------|--------|                                                                   |
| Takahashi et al., 2010       | SPD: 9/4 HC: 11/9             | Clinical                  | NL         | ROI    | Baseline: left caudal STG, PT\(↓\), no longitudinal changes in STG |

Abbreviations: Amyg, amygdala; Atlas, Atlas-based morphometry; BA, Brodmann area; HC, healthy control; Hipp, hippocampus; IFG, inferior frontal gyrus; IPG, inferior parietal gyrus; Med, medicated; MFG, middle frontal gyrus; MTG, middle temporal gyrus; NL, neuroleptic; NN, neuroleptic naive; NvM, never medicated; NA, not applicable; parahipp, parahippocampus; PT, planum temporale; ROI, region of interest; SFG, superior/middle/inferior frontal gyrus; SPD, schizotypal personality disorder; SPG, superior/inferior parietal gyrus; STG, superior temporal gyrus; UM, unmedicated; VBM, voxel-based morphometry; ↓, volume reduction; ↑, volume increase; →, no group difference.

variability in demographic factors that are known to influence brain volume such as age, sex, handedness, IQ, socioeconomic status (SES), and neuroleptic medication use.\(^{32-42}\)

Neuroleptic medications are of particular concern in light of nonhuman primate evidence suggesting that these medications can influence brain structure in and of themselves.\(^{33}\) Thus, a study of neuroleptic-naïve subjects with SPD may provide a clearer understanding of brain abnormalities in the schizophrenia spectrum.

Another important variable in SPD is sex because previous studies have demonstrated important sex differences in SPD, including a greater rate of lifetime prevalence of SPD in men (4.2%) compared with women (3.7%).\(^{4}\) In terms of symptom clusters, males with SPDs are most different from females with SPDs in interpersonal and social functioning, whereas females with SPDs are most different from males with SPDs in interper-
sonal relationships, having significantly fewer close relationships and also more prevalent negative symptoms associated with social deficits. Males with SPD also show a greater disturbance of verbal learning and abstraction than females with SPD. Not surprisingly, structural MRI studies have also shown sex differences on regional brain volumes in subjects with SPD, as well as in schizophrenia and in HC subjects. These sex differences indicate that we must separately investigate structural brain abnormalities and their symptom associations in men and women with SPD to avoid a sex confound. In our previous study, a voxel-based morphometry (VBM) analysis demonstrated volumetric gray matter (GM) reductions in several brain regions, including the left STG and left STG (9.2% reduction) compared with matched HC subjects.

In terms of men with SPD, our previous ROI analyses demonstrated GMV reductions in the cortex (6.9% reduction) and left STG (9.2% reduction) compared with matched HC subjects. Although limited, these findings suggest that cortical brain abnormalities in men with SPD are widespread but are more pronounced in some brain regions.

For the purpose of identifying local GMV abnormalities in SPD throughout the brain, a whole-brain VBM method is useful. However, there are only a few VBM studies that have investigated GMV reductions in neuroleptic-naive men with SPD and none providing clues as to reductions associated with negative symptoms, especially prominent in men.

The current whole-brain cross-sectional VBM analysis investigated volume differences in global and local GM in a large sample of 54 neuroleptic-naive men with SPD compared with 54 male HC subjects. To avoid potential confounds that could affect brain structure, the SPD and HC groups were carefully matched for sex, age, handedness, IQ, and the subject’s own SES and parental SES (Table 2). Based on the previous studies (Table 1), we speculated that men with SPD would show GMV reductions in multiple cortical regions—in similar regions but to a smaller extent than the reductions previously reported in patients with established schizophrenia. Once volume differences were confirmed, differences in the patterns of age-related GMV changes were evaluated between the groups to investigate whether these 2 groups would show similar patterns of age-related volume changes. Finally, correlation analyses were conducted between GMVs and clinical measures to investigate the biological implications of structural abnormalities in the men with SPD. Given the predominance of negative symptoms in males, we hypothesized that negative symptoms would be closely associated with GMV reductions, particularly in frontal regions known to play a role in emotion regulation and regions associated with social cognition. We have found these to be reduced in schizophrenia and associated with negative symptoms.

### METHODS

A total of 54 neuroleptic-naive men diagnosed as having DSM-III or DSM-IV SPD and 54 male control subjects were recruited from the community through advertisements. Of those, 6 male subjects with SPD and 14 male control subjects were used in our previous ROI study. Subjects with SPD were recruited via the following advertisement:

**Sixth sense/very shy:** A study at Harvard Medical School seeks right-handed people who believe they have ESP, telepathy, or a “sixth sense”; often mistake noises for voices; sense the presence of others when alone; have extreme social anxiety (or discomfort) in social situations involving unfamiliar people; and have few friends.

The SPD advertisement tapped the DSM-IV diagnostic criteria for SPD, which include (1) ideas of reference, (2) odd beliefs and superstitions or sixth sense, (3) abnormal perceptual experiences, (4) odd thinking and speech, (5) suspiciousness, (6) constricted affect, (7) odd and peculiar appearance or behavior, (8) no close friends, and (9) extreme social anxiety.

Of the 3001 individuals who responded to the SPD advertisement, 1536 male participants underwent an extensive telephone screening process that used the following inclusion criteria: (1) age between 18 and 55 years; (2) right handedness; (3) English as the primary language; (4) no history of neurologic disorder or loss of consciousness longer than 5 minutes; (5) no history of electroconvulsive therapy, drug or alcohol dependence in the past 5 years, or abuse in the past year; and (6) no history of using neuroleptics at any time or psychotropic medications in the past year.

### Table 2. Demographic Characteristics of the 108 Study Participants

<table>
<thead>
<tr>
<th></th>
<th>Mean (SD)</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Subjects With SPD</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, y</td>
<td>39.0 (10.5)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Education, y</td>
<td>15.1 (2.6)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IQ</td>
<td>109.0 (14.4)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Socioeconomic statusb</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Participant</td>
<td>3.2 (1.1)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parental</td>
<td>3.1 (1.3)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Handednessa</td>
<td>0.77 (0.23)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Control Subjects</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, y</td>
<td>36.8 (10.2)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Education, y</td>
<td>15.8 (2.7)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IQ</td>
<td>112.2 (15.3)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Socioeconomic statusb</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Participant</td>
<td>3.0 (1.4)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parental</td>
<td>3.1 (1.4)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Handednessa</td>
<td>0.80 (0.18)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviation:** SPD, schizotypal personality disorder.

*a* The degrees of freedom differ among variables owing to unavailability of data in some participants.

*b* Higher numbers represent higher socioeconomic status based on the Hollingshead Four Factor Index of Social Status.

*c* Handedness was evaluated using the Edinburgh Handedness Inventory, where right handedness is positive.
Of the 1536 subjects, 242 met the telephone inclusion criteria, including positive responses to at least 3 of the previously mentioned SPD criteria on screening questions. The Structured Clinical Interview for DSM-IV–Patient Edition (SCID)\textsuperscript{51} and its personality disorder version (SCID-II)\textsuperscript{52} were then used to make DSM-IV diagnoses, exclude Axis I psychotic and bipolar disorders from both groups, and exclude Axis I and Axis II diagnoses from control subjects. A total of 118 male subjects with SPD for demographic variables including age, disorder diagnosis. Control subjects were group matched with SPD. Male control subjects were recruited from the community, whereas female control subjects were recruited from a large, community-based clinic.

We have previously described in detail the clinical and demographic characteristics of the subjects with SPD.\textsuperscript{8,44} Interviews were conducted by either a licensed psychiatrist (C.C.D. or R.W.M) or a licensed psychologist (M.M.V. or M.E.S.). Interrater reliability for the diagnosis of SPD was high (κ = 0.89; n = 25).\textsuperscript{9}

Interviewers were trained to detect nuances of behavior and history and to ask follow-up questions to establish the correct diagnosis. In the rare instances in which the first interviewer was uncertain about the diagnosis, a second licensed psychiatrist or psychologist interviewed the subject, and a consensus was obtained. All 54 subjects with SPD who underwent MRI and other parts of the protocol met the full DSM-IV SPD diagnostic criteria (having ≥5 of the 9 characteristics). Subjects with SPD had a mean of 1.5 additional DSM-IV personality diagnoses, with the most common being paranoid (n = 19), avoidant (n = 16), obsessive-compulsive (n = 12), borderline (n = 10), and schizoid (n = 9) personality disorders. Fifteen men with SPD also met the criteria for Axis I disorders, including depression (n = 1); dysthymia (n = 9); generalized anxiety disorder (n = 4); and body dysmorphic disorder (n = 1).

Male control subjects were recruited from the community through a different advertisement and similarly underwent the SCID and SCID-II. Control participants had the additional inclusion requirement of no family history of psychotic or bipolar illness and no personal history of an Axis I or personality disorder diagnosis. Control subjects were group matched with subjects with SPD for demographic variables including age, Wechsler Adult Intelligence Scale–III IQ based on Vocabulary and Block Design subscales, handedness, and both the subject’s own and parental SES.\textsuperscript{33} The project was approved by the institutional review boards at Harvard Medical School and Boston Veterans Affairs Healthcare System; after a full description...
of the study was provided to the participants, written informed consent was obtained.

CLINICAL MEASURES

Clinical symptoms were measured using the Structured Interview for Schizotypy (SIS). Use of the SIS began in the middle of subject recruitment; therefore, only 21 of the 54 men with SPD completed the SIS. Based on our previous results from SPD on the most prominent positive and negative SIS items in our population and the Kendler criteria, we calculated the positive symptom score by summing scores of (1) ideas of reference, (2) magical thinking, (3) illusions, and (4) psychoticlike symptoms, while the negative symptom score summed scores of (1) social isolation, (2) introversion, (3) restricted emotion, and (4) sensitivity. There were no significant demographic differences between the male subjects with SPD with and without SIS scores (eFigure, http://www.jamapsych.com).

MRI PROCESSING

The MRI protocol used 2 pulse sequences on a 1.5-T MRI system (GE Medical Systems), as described. A 3-dimensional Fourier transformed spoiled-gradient-recalled acquisition sequence yielded a coronal series of contiguous 1.5-mm images (echo time, 5 milliseconds; repetition time, 35 milliseconds; repetition, 1; nutation angle, 45°; field of view, 24 cm; acquisition matrix, 256 × 256 × 124; voxel dimension, 0.9375 × 0.9375 × 1.5 mm).

IMAGE PREPROCESSING

The theory and algorithms of VBM using Statistical Parametric Mapping version 5 (SPM5) software (Wellcome Department of Cognitive Neurology) are well documented. In the present cross-sectional study, VBM was performed using the Diffeomorphic Anatomical Registration Through Exponentiated Lie (DARTEL) algebra tool in SPM5. After realigning the T1-weighted images so that the anterior commissure–posterior commissure line was horizontal and the midsagittal plane was vertical, the images were segmented by the unified segmentation approach in SPM5 into probability maps of gray and white matter and cerebrospinal fluid. These gray and white probability maps were then rigid-body aligned (3 rotations and 3 translations) according to the Montreal Neurological Institute (MNI) template and resampled into 1.5-mm isotropic voxels. These aligned images were still in their native space (www.fil.ion.ucl.ac.uk/spm/doc/manual.pdf). Next, a population GM was created by nonlinear registration of the resampled gray and white matter probability maps using DARTEL, which provided a higher dimensional (thus more accurate) warping procedure than that typically used in standard VBM. The white matter maps were used to achieve this improved registration, but they were not incorporated into the statistical analysis. The GM maps of each subject were then spatially nonlinearly normalized to the population template, and Jacobian modulated. To bring the final analysis into standard MNI space, the population GM template was registered to the MNI space. All the individual GM maps residing in the population template space were then coregistered to MNI using the same affine transformation. Finally, these images were smoothed with an 8-mm full-width at half maximum Gaussian kernel.

STATISTICAL ANALYSIS

To estimate group difference in global cortical GMV, individual cortical GMVs were calculated as per the procedure of Asami et al and Whitford et al. Consistent with our previous ROI study for male SPD, cortical GM was defined as all the cerebral GM, excluding the basal ganglia and thalamus. First, a binary image of cortical GM was created using the Wake Forest University PickAtlas toolkit. This binary image was then convolved with all subjects’ preprocessed GM images, and the volumes of cortical GM were calculated by summing the constituent smoothed modulated values. Finally, relative volumes were calculated using intracranial content (ICC) volumes measured by 3-dimensional slicer (www.slicer.org).

To investigate group differences in regional GMVs, the framework of the general linear model (GLM) was implemented using an analysis of covariance model. A 2-sample t test was applied, with ICC volume as a confounding covariate to correct for global anatomical variations. The resulting set of voxel values for each contrast constituted a statistical parametric map of the t statistic, SPM(t). The SPM(t) values were displayed at an uncorrected threshold of P < .001, with an extent threshold of 30 voxels for graphical reporting. The purpose of the current whole-brain VBM analysis was to identify local regions contributing to the global (cortical) GMV reduction in the male subjects with SPD observed in our previous study. Therefore, consistent with previous VBM analyses, false discovery rate–corrected P < .056 was applied to maintain a balance between appropriate correction for multiple comparisons, while also minimizing the potential for type 2 errors. In the text and tables, we discuss only those results surviving correction at this level.
CORRELATIONS BETWEEN VOLUMES AND AGE AND SYMPTOMS

As was done with the global cortical GMVs, the regional volumes were calculated as per the procedure of Asami et al.19 and Whitford et al.19 First, the regions for which the VBM analysis showed significant GMV differences between the 2 groups were extracted as a gray-scale image using the save option on the SPM5 graphic user interface. Then the gray-scale image was transformed into a binary image, and this binary image was parcellated into gyri using the Wake Forest PickAtlas toolkit and SPM image calculator. These binary images were then convolved with all subjects’ preprocessed GM images, and the volumes of each ROI-defined region were calculated by summing the constituent voxels.

To assess relationships between age and relative volumes of cortical and each ROI-defined GM in the SPD and HC groups, Spearman correlations were conducted, with \( P < .05 \) as significant (2 tailed). In addition, age by group interaction analyses were conducted for the cortical and each ROI-defined GM regions using analysis of variance, with cutoff \( P \) values of .05, to investigate whether the SPD and HC groups had similar patterns of age-related GMV reductions.

To evaluate contributions of structural changes to behavioral abnormalities in SPD, we evaluated associations between the positive and negative symptom scores derived from SIS and each ROI-defined GMV with significant reductions in those with SPD vs HC subjects. Based on our previous work, we hypothesized correlations with negative symptom scales. Results are reported as \( P < .05 \) (2 tailed).

RESULTS

There were no significant group differences in age, handedness, subject and parental SES, or IQ (Table 2).

GLOBAL CORTICAL GMV COMPARISON

There was a significant group difference in the global GMV; namely, the 54 neuroleptic-naive men with SPD showed smaller relative volume of the cortical GM compared with 54 matched male HC subjects (mean \( \pm \) SD), SPD: 42.0 \( \pm \) 3.9, HC: 43.5 \( \pm \) 3.1 [units are percentage of total ICC]; \( t_{106} = 2.23; P = .03 \).

VBM AND REGIONAL VOLUMES

Reflecting the result of group difference in the global GMV, the voxelwise whole-brain analysis showed significant widespread GMV reductions in the 54 men with SPD compared with the 54 HC subjects (false discovery rate–corrected \( P < .05 \)). These regions included (1) temporal regions of the bilateral superior and middle temporal gyri, fusiform gyrus, and left inferior temporal gyrus; (2) frontal regions of the bilateral superior and middle frontal...
tal gyri, orbitofrontal cortex, insula, cingulate gyrus (both anterior [subgenual and affective subregions] and posterior), and right precentral gyrus; and (3) parieto-occipital regions of bilateral postcentral gyrus, right supramarginal gyrus, precuneus, and inferior occipital gyrus. Although significant reductions were observed in the multiple cerebral regions, each reduction was small (typically < 300 voxels), as shown in Table 3, Figure 1, and the efigure. We found no region where the men with SPD had significantly larger volumes compared with the HC subjects.

There were no differences in regional GMVs between men with SPD with and without comorbid Axis I or Axis II disorders. Among the 11 subjects with SPD who also had first-degree relatives with psychosis, there was no significant GMV difference when compared with the participants with SPD without a family history of psychosis (eFigure).

**CORRELATION ANALYSIS**

**Relationships Between Age and Global and Regional GMVs**

The results are summarized in Table 4 and Figure 2. The Spearman correlation analyses showed statistically significant negative relationships between age and relative volumes of the cortical GM, as well as most of the ROI-defined GM regions, in both those with SPD and HC participants. However, analysis of variance showed no age by group interactions.

**Relationships Between Positive and Negative Symptom Scores and Regional GMVs**

There were no significant correlations between patients’ positive symptom scores and their GMV in any of the 26 ROIs. In contrast, as hypothesized, significant negative correlations were observed between the negative symptoms and the volume of 22 of the 26 ROIs in patients with SPD (Table 5, Figure 3, and the eFigure). This was unlikely to be a chance finding, given that the probability of obtaining 22 of 26 significant correlations with an alpha level of 0.05 was $P < 10^{-11}$ by the binomial theorem. Consequently, we then investigated the relationship between each of the 4 items on the SIS negative symptom scale and the regional volume of the 26 ROIs. As detailed in Table 5 and summarized here, significant negative correlations were observed between social isolation and 18 GM regions, restricted emotions and 11 regions, introversion and 13 regions, and sensitivity and 19 GM regions. The binomial distribution probability of 11 or more successes out of 26 trials with a probability of success of 0.05 was $P < 10^{-7}$, which remains significant for the 4 items after Bonferroni correction (eFigure).

**COMMENT**

This study demonstrated statistically significant GMV reductions in global and widespread brain regions in the 54 neuroleptic-naïve men with SPD compared with the 54 matched male HC subjects. To our knowledge, this is the first study to demonstrate such widespread GMV reductions in what is, we believe, the largest sample of neuroleptic-naïve men with SPD compared with HC subjects. Our extensive results, not observed in other VBM studies, may be owing to the improved sensitivity of the DARTEL method and the careful group matching by age, sex, handedness, IQ, and the subject’s own and parental SES. The global analysis finding of a significant GMV reduction in the cortex in the men with SPD was in line with our previous result, arrived at using a ROI method. In the voxelwise analysis, significant widespread GMV reductions were discovered in multiple cortical regions in the men with SPD compared with HC subjects. The size of each reduced region was comparatively small, in contrast to previous studies that have identified widespread volumetric GM reductions in patients with schizophrenia. Relative to women with SPD, the men with SPD showed GMV reductions in widespread local brain regions.

In the frontal lobe, volume reductions were confirmed in several frontal surface gyri: bilateral superior (mainly the medial region), middle, orbitofrontal, and...
right precentral. Previous studies have suggested that the volume of frontal regions, particularly Brodmann area 10, may be preserved in subjects with SPD. However, we found that men with SPD had GMV reductions at least in small regions in the medial frontal regions that were associated with the default mode network. Within frontal limbic regions, SPD evinced smaller GMVs in the bilateral insula, affective and subgenual subregions of the anterior cingulate gyrus, and posterior cingulate gyrus, similar to previous studies.

In the temporal lobe, the subjects with SPD showed volume reductions in the bilateral superior and middle temporal gyri, fusiform gyri, and left inferior temporal gyrus compared with the HC subjects. The volume reduction in the STG is the most consistent finding in both the ROIs and VBM analyses in SPD; volume reductions in the other temporal regions have also been reported previously. The fusiform gyrus is thought to be important in facial recognition, and our previous MRI–evoked-potential studies have demonstrated these structural-cognitive relationships in schizophrenia. Subjects with SPD are also thought to have deficits of facial recognition; the finding of fusiform gyrus volume reductions might be an anatomical substrate of poor facial recognition in SPD. Although our previous ROI did not demonstrate a difference in fusiform GMV, the voxel by voxel approach, as well as larger subject sample, could detect small abnormalities in fusiform gyrus in SPD. In parietal and occipital lobes, this study provided new evidence that men with SPD showed GMV reductions in the bilateral postcentral gyrus, precuneus, right supramarginal gyrus, and inferior occipital gyrus compared with HC subjects. Lateral parietal regions are also believed to be related to the default mode network, while the inferior occipital gyrus and fusiform gyrus are believed to be involved in the ventral stream of visual processing. Thus, it is feasible that abnormalities in this region might also be related with poor facial recognition in individuals with SPD.

While the neurobiological mechanism underlying the smaller GMVs in SPD is unknown, it is consistent with the finding of GMV reductions observed in schizophrenia, but without the postonset progression. Neuropathologic investigations indicate the basis of GMV reductions in schizophrenia is neuropil reduction. We have speculated that, in schizophrenia, there is a cortical circuit abnormality of deficient gamma-aminobutyric acidergic recurrent inhibition that may result in excito-toxic GMV loss. This mechanism could promote progressive GMV reductions in schizophrenia, we speculate that SPD has a less severe alteration in circuitry, therefore shows no progressive GMV changes.

The absence of progression in SPD is supported by a recent longitudinal MRI study showing no progressive GMV changes in the STG after a 2.9-year interval in the patients with SPD compared with HC subjects. In our

### Table 5. Results of Correlation Analyses between Relative Volumes of the ROI-defined Gray Matter Regions and SIS Negative Symptom Scores in the Male Subjects With SPD

<table>
<thead>
<tr>
<th>Anatomic Location</th>
<th>Negative Symptom (n = 21)</th>
<th>Social Isolation (n = 21)</th>
<th>Restricted Emotions (n = 21)</th>
<th>Introspection (n = 21)</th>
<th>Sensitivity (n = 21)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Rho</td>
<td>P Value</td>
<td>Rho</td>
<td>P Value</td>
<td>Rho</td>
</tr>
<tr>
<td>L superior temporal gyrus</td>
<td>-0.68</td>
<td>0.01 a</td>
<td>-0.56</td>
<td>0.03 a</td>
<td>-0.49</td>
</tr>
<tr>
<td>L middle temporal gyrus</td>
<td>-0.48</td>
<td>0.03 b</td>
<td>-0.35</td>
<td>0.06</td>
<td>-0.47</td>
</tr>
<tr>
<td>L fusiform gyrus</td>
<td>-0.63</td>
<td>0.02 a</td>
<td>-0.53</td>
<td>0.11</td>
<td>-0.56</td>
</tr>
<tr>
<td>L superior frontal gyrus</td>
<td>-0.67</td>
<td>0.01 a</td>
<td>-0.62</td>
<td>0.03 a</td>
<td>-0.47</td>
</tr>
<tr>
<td>L middle frontal gyrus</td>
<td>-0.56</td>
<td>0.008 a</td>
<td>-0.57</td>
<td>0.007 a</td>
<td>-0.43</td>
</tr>
<tr>
<td>L orbitofrontal cortex</td>
<td>-0.71</td>
<td>&lt;0.001 a</td>
<td>-0.70</td>
<td>&lt;0.001 a</td>
<td>-0.44</td>
</tr>
<tr>
<td>L insula</td>
<td>-0.45</td>
<td>0.04 b</td>
<td>-0.61</td>
<td>0.004 a</td>
<td>-0.45</td>
</tr>
<tr>
<td>L anterior cingulate gyrus</td>
<td>-0.58</td>
<td>0.006 a</td>
<td>-0.57</td>
<td>0.008 a</td>
<td>-0.49</td>
</tr>
<tr>
<td>L posterior cingulate gyrus</td>
<td>-0.53</td>
<td>0.01 b</td>
<td>-0.49</td>
<td>0.02 b</td>
<td>-0.56</td>
</tr>
<tr>
<td>R superior frontal gyrus</td>
<td>-0.63</td>
<td>0.002 b</td>
<td>-0.60</td>
<td>0.004 a</td>
<td>-0.45</td>
</tr>
<tr>
<td>R middle frontal gyrus</td>
<td>-0.63</td>
<td>0.002 b</td>
<td>-0.65</td>
<td>0.005 a</td>
<td>-0.56</td>
</tr>
<tr>
<td>R precuneus</td>
<td>-0.66</td>
<td>0.01 a</td>
<td>-0.59</td>
<td>0.005 a</td>
<td>-0.51</td>
</tr>
<tr>
<td>R orbitofrontal cortex</td>
<td>-0.74</td>
<td>&lt;0.001 a</td>
<td>-0.73</td>
<td>&lt;0.001 a</td>
<td>-0.44</td>
</tr>
<tr>
<td>R insula</td>
<td>-0.47</td>
<td>0.03 b</td>
<td>-0.61</td>
<td>0.004 a</td>
<td>-0.47</td>
</tr>
<tr>
<td>R anterior cingulate gyrus</td>
<td>-0.72</td>
<td>&lt;0.001 a</td>
<td>-0.68</td>
<td>0.001 a</td>
<td>-0.65</td>
</tr>
<tr>
<td>R posterior cingulate gyrus</td>
<td>-0.64</td>
<td>0.002 a</td>
<td>-0.61</td>
<td>0.004 a</td>
<td>-0.47</td>
</tr>
<tr>
<td>R postcentral gyrus</td>
<td>-0.61</td>
<td>0.004 a</td>
<td>-0.60</td>
<td>0.008 a</td>
<td>-0.51</td>
</tr>
<tr>
<td>R precuneus</td>
<td>-0.55</td>
<td>0.01 a</td>
<td>-0.57</td>
<td>0.007 a</td>
<td>-0.47</td>
</tr>
<tr>
<td>R postcentral gyrus</td>
<td>-0.61</td>
<td>0.003 a</td>
<td>-0.57</td>
<td>0.007 a</td>
<td>-0.56</td>
</tr>
<tr>
<td>R precuneus</td>
<td>-0.51</td>
<td>0.02 b</td>
<td>-0.52</td>
<td>0.02 a</td>
<td>-0.45</td>
</tr>
<tr>
<td>R supramarginal gyrus</td>
<td>-0.60</td>
<td>0.004 a</td>
<td>-0.54</td>
<td>0.01 b</td>
<td>-0.53</td>
</tr>
<tr>
<td>R inferior occipital gyrus</td>
<td>-0.50</td>
<td>0.02 b</td>
<td>-0.53</td>
<td>0.01 b</td>
<td>-0.54</td>
</tr>
</tbody>
</table>

Abbreviations: L, left; R, right; ROI, region of interest; SIS, Structured Interview for Schizotypy; SPD, schizotypal personality disorder.

\( a\) P < .01.
\( b\) P < .05.
data, the similar patterns of the age-related volume de-
cline between the 2 groups may provide provisional evi-
dence that, in contrast to patients with schizophrenia,
male subjects with SPD do not show progressive loss on
neocortical and almost all regional volumes,\textsuperscript{36,78,79} al-
though it is necessary to confirm our findings in a lon-
gitudinal analysis. This caveat notwithstanding, our re-
sults point to an intriguing difference between
schizophrenia and the spectrum disorder of SPD, a dif-
ference that invites further neurobiological study.

Finally, the correlation analyses, although tentative be-
cause of the number of correlations performed, demon-
strated relationships between the local GMV reductions
and behavioral abnormalities in the men with SPD. This
confirmed our prediction of the association between nega-
tive symptoms and GMVs, a prediction generated be-
because severe negative symptoms and fewer close friends
are the most salient and prominent features of male SPD,\textsuperscript{44}
thus most likely to be associated with volumetric reduc-
tions. The association of reduced STG and fusiform gy-
rus volumes with negative symptoms is of interest in sug-
gest that deficits in early sensory processing may be
related to negative symptoms. We noted also that pre-
vious studies have reported that negative symptoms are
among the risk factors for social dysfunction, lower qual-
ity of life, and suicide in subjects with schizophrenia spec-
trum disorders.\textsuperscript{80-82} Because studies have shown that in-
dividuals with SPD have worse social function and higher
frequency of attempted suicide,\textsuperscript{83,84} this association of
negative symptoms and volumetric reduction provides
insight into the pathophysiology of SPD.

To our knowledge, there are no previous MRI stud-
ies reporting widespread structure-negative symptom re-
lationships in men with SPD. In previous studies—
which either included only female subjects or combined
male and female subjects with SPD—only a small num-erv of regions have been demonstrated to have a rela-
tionship with negative symptoms. Examples of these re-
gions include Brodmann area 22 (STG), showing the
negative association with the interpersonal impairment
score (which involved no close friends\textsuperscript{29}) and the cau-
date, showing the relationship with restricted emo-
tions.\textsuperscript{15} In contrast, our current study revealed that the
widespread GM regions—not limited local regions—
were associated with the negative symptoms. These GM
regions included frontal (mainly medial regions), fron-
tolimbic, temporal, and parietal regions. These regions
have been reported to have associations with negative
symptoms in schizophrenia.\textsuperscript{85-88} We note the negative
symptom—GM association did not definitively indicate
that the GMV changes caused the negative symptoms be-
cause various extraneous factors (eg, social factors) could
be causative of, or could potentiate, GMV changes. Fi-
ally, with respect to the GMV changes, because this
never-medicated subject population excluded medica-
tion as a confound, we believe the observed GMV-
negative symptom association is important in providing information on the pathophysiology of schizophrenia spectrum disorders.

Of particular interest to the negative-symptom profile is its relationship to the default network and the location of SPD GM deficits. Recent functional MRI studies and fractionation analyses suggest the core of the default network is the posterior cingulate and anterior medial prefrontal cortex, regions prominently represented in GM deficits in SPD. The fractionation analysis also identified default network components related to self in the present; the SPD regions with GMV deficits had a strong overlap with this aspect of the self, including the dorsomedial (anterior cingulate) prefrontal cortex, temporoparietal junction regions, and lateral temporal cortex, although the temporal pole did not show a deficit in SPD. These SPD regions also showed correlations with negative symptoms. Interestingly, functional MRI studies point to abnormalities in the resting-state default network in schizophrenia and, of particular note, in first-degree relatives of persons with schizophrenia. While there are many ways of conceptualizing the default network activity, one prominent theory is that it is related to social cognition because the brain regions in the default network and those active in social cognition overlap. Thus, we hypothesized that the prominent social deficits/negative symptoms shown in SPD may be, at least in part, related to GM abnormalities in the default network, regions that showed association with negative symptoms.

The present data indicate that contributions to negative symptoms likely also stem from a defective anatomic substrate in other, widespread brain regions in addition to the default network. Abnormalities in GMV in auditory, somatosensory, and fusiform regions were associated with negative symptoms, regions involved in sensory and language processing, and possibly interfering with social interaction through defective processing of social cues. Moreover, as reviewed by us in our article on orbitofrontal cortex in schizophrenia, abnormalities in this region have consistently been associated with social deficits, as we found in the SPD population.

The correlation analyses between negative symptoms and regional volumes, although hypothesis driven, should be considered exploratory owing to the number of correlations, therefore needing confirmation in future studies. A longitudinal study would offer stronger evidence that men with SPD do not (or do) have progressive GMV loss.

This study revealed volumetric GM reductions and symptom correlations in a large and neuroleptic-naive sample of single-sex (male) subjects with SPD. A correlation analysis indicated that the widespread GMV reductions were strongly associated with negative symptoms in men with SPD. These reductions also overlapped with the default network and the regions active in social cognition and perception of social cues, suggesting a possible anatomic substrate of negative symptoms. The absence of an age-related difference in GM change between those with SPD and HC subjects suggested that, unlike schizophrenia, there is no progressive volume reduction in SPD. Future longitudinal studies would be useful in confirming this important point of difference between the 2 disorders.

Submitted for Publication: June 6, 2012; final revision received June 6, 2012; accepted August 21, 2012.

Published Online: February 6, 2013. doi:10.1001/jamapsychiatry.2013.665

Author Affiliations: Laboratory of Neuroscience, Clinical Neuroscience Division, Department of Psychiatry, Boston Veterans Affairs Healthcare System, Brockton Division, Brockton (Drs Asami, Bouix, Dickey, Niznikiewicz, Shenton, Voglmaier, and McCarley); Psychiatry Neuroimaging Laboratory, Department of Psychiatry, Brigham and Women’s Hospital, Boston (Drs Asami, Whitford, Bouix, Dickey, Niznikiewicz, and Shenton), Harvard Medical School, Massachusetts; and School of Psychology, University of New South Wales, Sydney, New South Wales, Australia (Dr Whitford).

Correspondence: Robert W. McCarley, MD, Department of Psychiatry, 116A, Boston Veterans Affairs Healthcare System, Brockton Division, Harvard Medical School, 940 Belmont St, Brockton, MA 02301 (robert_mccarley@hms.harvard.edu).

Conflict of Interest Disclosures: None reported.

Funding/Support: This study was supported by Merit Awards from the Department of Veterans Affairs (Drs Shenton and McCarley); a Research Enhancement Award (Drs Shenton and McCarley); a Middleton Award (Dr McCarley); a Veterans Affairs Advanced Career Development Award (Dr Dickey); and grants K05MH070047 and R01MH50740 (Dr Shenton) and R01 MH 40799 and R01 MH 052807 (Dr McCarley) from the National Institute of Mental Health. Dr Whitford’s work is supported by an Overseas-Based Biomedical Training Fellowship from the National Health and Medical Research Council of Australia (NHMRC 520627), administered through the Melbourne Neuropsychiatry Centre at the University of Melbourne, Australia.

Online-Only Material: The eFigure is available at http://www.jamapsych.com.

Additional Contributions: We acknowledge Marie Fairbanks for her administrative support on this study.

REFERENCES

23. Haznedar MM, Buchsbaum MS, Haznedar MM, New A, Shihabuddin L, Seto H, Kura- 

24.leet EA, Buchsbaum MS, Haznedar MM, New A, Shihabuddin L, Seto H, Cortical gray and white matter volume in unmedicated schizotypal and schizo-

25. Goldstein KE, Hazlett EA, New A, Haznedar MM, Shihabuddin L, Seto H, Cortical gray and white matter volume in unmedicated schizotypal and schizo-


28. Gur RE, Cowell P, Turetsky BI, Gallacher F, Cannon T, Bilker W, Gur RC. A fol-
low-up magnetic resonance imaging study of schizophrenia: relationship of neu-


33. Ivanovic DM, Leiva BP, Perez HT, Olaveses MG, Diaz NS, Urrutia MS, Almagia AF, Toro TD, Miller PT, Bosch EO, Larrain GD. Head size and intelligence, learn-


35. Nakamura M, Salisbury DF, Hayasaka Y, Bouix S, Polli KM, Yoshida T, Koo MS, Shenton ME, McCarley RW. Neocortical gray matter volume in first-episode schizo-


39. Dickey CC, McCarley RW, Niznikiewicz MA, Voglmaier MM, Seidman LJ, Kim S, Shenton ME. Clinical, cognitive, and social characteristics of a sample of neuroleptic-


41. Yuscel M, Stuart GW, Maruff P, Velakoulis D, Crowe SF, Savage G, Pantelis C. Hemispheric and gender-related differences in the gross morphology of the an-

42. Goldstein JM, Seidman LJ, O'Brien LM, Horton NJ, Kennedy DN, Makris N, Cavie-
ess VS Jr., Faroane SV, Tsou TS, EMMT. Impact of normal sexual dimorphisms on sex differences in structural brain abnormalities in schizophrenia assessed by magnetic resonance imaging. Arch Gen Psychiatry. 2002;59(2):154-164.


©2013 American Medical Association. All rights reserved.

Downloaded From: by a Non-Human Traffic (NHT) User on 12/05/2018
67. Tahmasebi AM, Abolmaesumi P, Zheng ZZ, Munhall KG, Johnsrude IS. Reduc-


55. Kendler KS, Ochs AL, Gorman AM, Hewitt JK, Ross DE, Mirsky AF. The struc-

49. Asami T, Boux S, Whitford TJ, Shenton ME, Salisbury DF, McCarley RW. Lon-

gitudinal loss of gray matter volume in patients with first-episode schizophrenia:

48. Neugebauer C, Grant JD, Shenton ME, McCarley RW, Cannon TD, Fennig KD. 

47. Wriston KC, Johnson KL, Ho CT, Keltner C, Shenton ME, McCarley RW. 

46. Barta S, Rideout NA, Shenton ME, McCarley RW, Fennig KD. A voxel-based 

45. Choi Y, Chang JH, Lee KB, Kim SH, Kim KS, Kwon D, Kim JY. Voxel-based anal-

44. Biado-Madalina D, Schmidt C, Giannakopoulos P. Orbitofrontal cortex discon-

43. Green AI, Nieto-Castanon A, LaViolette P, Wojcik J, Gabrieli JD, Wrase T, 

42. Clasen LS, Whitfield-Gabrieli S, Lim KO, Benke T, Lee J, Brown C, Zou Y, 

41. Whitfield-Gabrieli S, Thermenos HW, Milanovic S, Tsuang MT, Faraone SV, McCarley 

40. Whitfield-Gabrieli S, Thompson PM, Verbanac A, Llano LE, Allin JG, 

39. Grant JD, Shenton ME, McCarley RW, Cannon TD, Fennig KD. Voxel-based anal-

38. Paulus M, Gatenby JC, Nuechterlein KH, Miller E, Green A, Weickert CS, 

37. Marder SR, Gustaffson HK, Faraone SV, Young WC, Alvir JP, Boulenger JV, 

36. Nuechterlein KH, Drury J, Banerjee S, Marder SR, Gatenby JC, Faraone SV, 

35. Vogeley K, Schilbach L, Eickhoff SB, Rotarska-Jagiela A, Fink GR. Minds at rest? 


33. Mallya A, Shenton ME, McCarley RW. Orbitofrontal volume deficit in schizophre-


31. Wang W, Gall D, Bryant DJ, Mehta MD, Wisniewski SR, Zaninelli D, 

30. Poldrack RA, Grafton ST, Gazzaley A, Small SL, Kiehl KA, Whalen PJ, 

29. Varsh S, Poldrack RA, Grafton ST, Gazzaley A, Small SL, Kiehl KA, Whalen PJ, 

28. Kondratyuk ES, Bobrova DA, Soldatov AV, Kachurina NA, Kholodov AI, 

27. Scott W, Yang S, Carrillo MH, Smith AE. Voxel-based morphometry analysis of 

26. Amador X, Gluckman E, Wood SJ, McGorry PD, Velakoulis D, Kapur S. The role of 

25. Goodbody S, Hedges D, Mawlawi O, Redmond SC, DiBartolomeo M, 

24. Iacono GW, McGue M, Skodol AE, Pérez-Stable EJ. Schizotypal personality disor-

23. McCarley R, Velakoulis D, Velakoulis V. Voxel-based morphometry analyses of 

22. Bora E, Zuccato C, Addis DR, Storace S, Colla C, Marzocchi A, Xidou V, 


19. Witek I, Crow TJ, Jones PB, O'Dwyer S, Dobbs S, Sadleir L, Ma W, 

18. Witek I, Crow TJ, Jones PB, O'Dwyer S, Dobbs S, Sadleir L, Ma W, 

17. Witek I, Crow TJ, Jones PB, O'Dwyer S, Dobbs S, Sadleir L, Ma W, 


15. Tyszczuk A, Sloane D, Muller S, Whitfield-Gabrieli S, Hakonarson H, Kiehl KA, 

14. Varsh S, Poldrack RA, Grafton ST, Gazzaley A, Small SL, Kiehl KA, Whalen PJ, 


©2013 American Medical Association. All rights reserved.